Login to Your Account

Clinic Roundup

Friday, September 9, 2011
Sagene Pharmaceuticals Inc., of Oldsmar, Fla., completed a pre-investigational new drug meeting with the FDA regarding erectile dysfunction drug SPI-1972, which combines the FDA-approved MAO-B inhibitor selegiline with a PDE-5 inhibitor such as Viagra (sildenafil, Pfizer Inc.) or Cialis (tadalafil, Eli Lilly and Co.).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription